Completed PHASE1/PHASE2 INTERVENTIONAL NCT00002509

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

HIGH-DOSE CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CARBOPLATIN FOLLOWED BY RESCUE WITH AUTOLOGOUS BONE MARROW AND AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH POOR PROGNOSIS BREAST CANCER

Sponsor: Fox Chase Cancer Center

Conditions Breast Cancer

Interventions autologous bone marrow transplantation carboplatin cyclophosphamide etoposide filgrastim mesna peripheral blood stem cell transplantation

Updated 5 times since 2017 Last updated: Sep 30, 2010 Started: Nov 30, 1991 Primary completion: Dec 31, 2003 Completion: Dec 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by Fox Chase Cancer Center and has accumulated 5 data snapshots since 1991. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 1991

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fox Chase Cancer Center
Temple University

Data source: Temple University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States